Asymptomatic stage of human immunodeficiency virus infection is the optimal timing for its management with Traditional Chinese Medicine

Journal of Traditional Chinese Medicine

Volumn 35, Issue 2, 2015, Pages 244-248

  Chen, Xiumin ^a   Yuan, Qingting ^b   Liu, Zhibin ^a,c   Yang, Jiping ^a,c   Xu, Liran ^a,c   Guo, Huijun ^a,c  

^a THE FIRST AFFILIATED HOSPITAL OF HENAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b HENAN UNIVERSITY OF CHINESE MEDICINE   (China)

^c Key Lab of Viral Dis Prevention and Treatment of Traditional Chinese Medicine of Henan Province   (China)

Author keywords

Acquired immunodeficiency syndrome; Antiretroviral therapy; Asymptomatic infections; Chinese traditional; Highly active; Medicine

Indexed keywords

ANTIRETROVIRUS AGENT; CHINESE DRUG; HERBACEOUS AGENT;

AIDS PATIENT; ASYMPTOMATIC INFECTION; CD4 LYMPHOCYTE COUNT; CHINESE MEDICINE; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; ANIMAL; ASYMPTOMATIC DISEASES; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; TIME; VIROLOGY;

ANIMALS; ASYMPTOMATIC DISEASES; DRUGS, CHINESE HERBAL; HIV INFECTIONS; HIV-1; HUMANS; TIME FACTORS;

EID: 84945294671     PISSN: 02552922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Sepkowitz KA. AIDS-the first 20 years. N Engl J Med 2001; 344(23): 1764-1772.
2. Munier CM, Andersen CR, Kelleher AD. HIV vaccines: progress to date. Drugs 2011; 71(4): 387-414.
3. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360(7): 692-698.
4. Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced- intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013; 207(11): 1694-1702.
5. Palella FJ JR, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338(13): 853-860.
6. AIDS Group. Society of Infectious Disease, Chinese Medical Association. Guideline of diagnosis and treatment for AIDS. Chin J Clin Infect Dis 2011; 4(6): 231-330.
7. de Boer IM, Prins JM, Sprangers MAG, Smit C, Nieuwkerk PT. Self-reported symptoms among HIV-infected patients on highly active antiretroviral therapy in the ATHENA cohort in the Netherlands. HIV Clin Trials 2011; 12(3): 161-170.
8. Anglemyer A, Rutherford G W, Easterbrook P J, et al. Early initiation of antiretroviral therapy in HIV-infected adults and adolescents: A systematic review. AIDS 2014; 28 Suppl 2: S105-S118.
9. Lundgren JD, Babiker AG, Gordin FM, Borges ÁH, Neaton JD. When to start antiretroviral therapy: The need for an evidence base during early HIV infection. BMC Med 2013; 11(1): 148.
10. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Online, 2013-6-30, cited 2014-1-1; 1:132 screens. Available from URL: http://www.who.int/HIV/pub/guidelines/arv2013/download/en/.
11. European AIDS Clinical Society. Guidelines, version 7.1, Online, 2014-11-1, cited 2015-1-8; 1:8. Available from URL: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html.
12. Williams I, Churchill D, Anderson J, et al. British HIV association guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012. HIV Medicine 2014; 15 (Suppl 1): 1-85.
13. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308(4): 387-402.
14. Gong MC, Yang F, Li ZT, Li TS. Benefit and risk of the early start to highly active antiretroviral therapy in infected HIV-1. Zhong Hua Nei Ke Za Zhi 2010; 49(8): 710-713.
15. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365(6): 493-505.
16. Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis 2010; 50(11): 1532-1538.
17. Jaén Á, Esteve A, Miró J M, et al. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain). J Acquir Immun Defic Syndr 2008; 47(2): 212-220.
18. PalellaJr FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immun Defic Syndr 2006; 43(1): 27-34.
19. Gras L, Kesselring A M, Griffin J T, et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immun Defic Syndr 2007; c5(2): 183-192.
20. Braithwaite RS, Roberts MS, Goetz MB, et al. Do benefits of earlier antiretroviral treatment initiation outweigh harms for individuals at risk for poor adherence? Clin Infect Dis 2009; 48(6): 822-826.
21. Sun DZ, Li SD, Liu UY, Yang MH. Differences in the origin of philosophy between Chinese medicine and western medicine: exploration of the holistic advantages of Chinese medicine. Chin J Integr Med 2013; 19(9): 706-711.
22. Zhang MM, Liu XM, He L. Effect of integrated traditional Chinese and Western medicine on SARS: A review of clinical evidence. World J Gastroenterol 2004; 10(23): 3500-3505.
23. Wang C, Cao B, Liu QQ, et al. Oseltamivir compared with the Chinese traditional therapy Maxingshigan-Yinqiaosan in the treatment of H1N1 influenza: A randomized trial. Ann Intern Med 2011; 155(4): 217-225.
24. Tu JW, Dong MJ, Liu ZY, Li Y, Chen J. A control study on Chinese medicine for light of common type of epidemic encephalitis B. Zhong Yi Za Zhi 2013; 54(12): 1028-1030.
25. Deng X, Liang J, Wu FS, Li YB, Tang YF. Effects of the Ganning formula on liver fibrosis in patients. J Tradit Chin Med 2011; 31(4): 282-287.
26. Wang J, Zou W. Recent advances of HIV/AIDS treatment with traditional Chinese medicine in China. J Tradit Chin Med 2010; 30(4): 305-308.
27. Shi D, Peng ZL. Randomized double blind placebo paralleled clinical research on HIV/AIDS with Qiankunning tablets. Zhong Yi Yao Xue Kan 2003; 21(9): 1472-1474.
28. Liu Z, Wang J, Lin HS, Li Y. Effect of immune 2 with highly active antiretroviral treatment on immune function of HIV/AIDS patients with poor immune reconstitution. Zhong Guo Zhong Yao Za Zhi 2013; 38(15): 2458-2462.
29. Wang J, Tang YL, Lin HS, Wu XF, Liu J, Li Y. Effect of immune No. 2 on the immune reconstitution in patients with HIV/AIDS after highly active antiretroviral treatment: A randomized double blind placebo controlled clinical trial. Chin J Integr Med 2013; 19(5): 340-346.
30. Huang L, Zhou CJ, Liang FL, Lu XE, Wang ZM. Treatment of HAART associated hepatic function damage with Dangguishaoyao powder in 48 AIDS patients. Zhong Yi Yan Jiu 2007; 20(8): 55-56.
31. Xie SP, Guo HJ, Xu QL, Guo YM, Pan WQ. Effect of Aikang capsule on life quality in HIV/AIDS patients. Shanghai Zhong Yi Yao Za Zhi 2007; 41(9): 15-18.
32. Jiang SQ, Sun HX, Xu YM, Jiang YL, Pei JW, Wang HL. Effects of Jingyuankang capsules on leukocyte level in AIDS patients. J Tradit Chin Med 2011; 31(4): 32-35.
33. Liu XW. Several thoughts on the traditional Chinese medicine perspective of AIDS in asymptomatic HIV-infected. Zhong Hua Zhong Yi Yao Za Zhi 2013; 28(2): 454-456.
34. Xu LR, Yang XP, Guo HJ, et al. Study on quality of life of asymptomatic HIV infected persons with Traditional Chinese Medicine. Zhong Guo Zhong Yao Za Zhi 2013; 38 (15): 2480-2483.
35. Jiang F, Zhang RX, Gu ZF, et al. Fuzhengpaidu granule regulates immune activation molecules CD38 and human leukocyte antigen-D related on CD4 + and CD8 + T cells in patients with acquired immunodeficiency syndrome/human immunodeficiency virus. J Tradit Chin Med 2013; 33 (4): 439-443.
36. National Science and Technology Report service. Research of the effect of early TCM intervention on asymptomatic HIV infectors. 2014. Online, 2014-01-01, cited2014- 05-28; 1: 67 screens.Available from URL:http://www.nstrs.org.cn/Login.aspx.
37. Li Q, Xu QL, Guo HJ. Some thoughts on present clinical research of HIV/AIDS. Shi Jie Ke Xue Ji Shu Zhong Yi Yao Xian Dai Hua 2013; 15(5): 901-904.
38. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Online, 2014-11-13 cited 2015-3-28; 1:46 screens. Available from URL: http://AIDSinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
39. Shao MY, Xu LR. The design method based on TCM pattern differentiation of reducing the incidence of asymptomatic HIV carrier. Nanjing Zhong Yi Yao Da Xue Xue Bao (Natural Science) 2010; 26(4): 249-251.